Aligos Therapeutics preparing $100M IPO

Aligos Therapeutics (ALGS) has filed a preliminary prospectus for a $100M IPO.

The South San Francisco, CA-based biopharmaceutical company leverages its oligonucleotide and small molecule platforms to develop drugs for use in combo regimens for viral and liver diseases. Lead program, comprised of four candidates, is aimed at a functional cure for chronic hepatitis B virus (HBV) infection. Another program, with one candidate at present, is focused on NASH, currently preclinical.

2020 Financials (6 mo.): Operating Expenses: $42.0M (+99%); Net Loss: ($40.8M) (-104%); Cash Burn: ($38.0M) (-108%).


READ  Pidilite Industries Q4 results: Reports 33% dip in net profit


Please enter your comment!
Please enter your name here